Subscribe to Search results

Professor Bloom argued publicly and very strongly for steps to be taken to reduce or eliminate the risk of HIV transmission, without arguing that there was yet no conclusive proof that heat treatment would necessarily be safe.

Published on:

The Haemophilia Society informed the DHSS that they wanted to discuss - among other subjects - the "no ban on the importation of American concentrates."

Published on:

Dr Walford referred to "the cries from some quarters to ban the import of Factor VIII". It was not universally accepted at the time.

Published on:

The functions of the Secretaries of State for Health of the UK, as Licensing Authority, under the Medicines Act 1968, were discharged by the Medicines Division of the DHSS.

Published on:

The Sub-Committee on Biological Products ("CSM(B)") worked on its own.

Published on:

The CSM(B) members would know the views of the Medicines Division staff, for their reports did not simply summarise any danger but expressed a view on it.

Published on:

Professor Sir Michael Rawlins did not know why the CSM had not pressed for greater transparency at an earlier stage.

Published on:

Professor Sir Michael Rawlins believed side effects of medicine "was a judgment of balancing safety and efficacy."

Published on:

Professor Sir Michael Rawlins stated that FDA approval was given if the licensing body had found it was appropriate and therefore it carried weight to the product.

Published on:

Professor Sir Michael Rawlins stated in his oral evidence that Dr Galbraith's May 1983 letter and paper should have been provided to the CSM(B).

Published on:

Professor Sir Michael Rawlins (CSM) stated in his oral evidence that if they had known AIDs was caused by a virus and how donors were pooled in the US, they would have acted differently regarding the importation of commercial factor concentrates.

Published on:

At a meeting of the Blood Products Advisory Committee, Dr Michael Rodell (Armour) indicated that it was clear that pools might have been contaminated. He also stated that persons who were paid for their plasma had it collected 40 to 60 times per year, on average.

Published on:

Professor Bloom wrote to Armour to express concerns that concentrate prepared from plasma collected before March 24 might be preferentially exported from the USA.

Published on:

In a letter, K.W FItch (Armour) stated that Armour had not preferentially exported plasma stocks out of the USA which had been produced from plasma collected prior to the FDA ruling.

Published on:

Dr Walford asked Dr Fowler of Medicines Division whether the supply of blood comprising pre-March plasma could be resisted.

Published on:

Dr Walford considered it possible that concentrates made from the "safer" plasma might be retained for use in the US whilst those older stocks were dumped on export markets such as the UK. Dr Walford also asked if there was any way, perhaps by new labelling requirements to prevent this.

Published on:

In a letter, Dr Oliver suggested a meeting to discuss blood product supplies and stated that any blood products imported from USA would ideally be made from plasma collected after March 1983.

Published on:

At a DHSS meeting regarding AIDs it was stated that new legal restrictions to prevent the dumping of pre-March '83 plasma would have significant practical difficulties.

Published on:

An information sheet about AIDS prepared by Dr Diana Walford was provided to John Patten.

Published on:

An information sheet about AIDS prepared by Dr Diana Walford was provided to Lord Glenarthur.

Published on: